Last reviewed · How we verify
Synergy for Staphylococcal Infections
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for Staphylococcal Infections patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for Staphylococcal Infections treatment landscape brief
- Synergy for Staphylococcal Infections treatment updates RSS
Frequently asked questions about Synergy for Staphylococcal Infections
What drugs treat Synergy for Staphylococcal Infections?
Tracked treatments include Ramycin, Garamycin, Tobi, Vantobra, Gentamicin, Nebcin.
What is the treatment for Synergy for Staphylococcal Infections?
Standard treatment for Synergy for Staphylococcal Infections includes Ramycin, Garamycin, Tobi, Vantobra, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for Staphylococcal Infections patent cliff · Synergy for Staphylococcal Infections CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing